Procaps Group (PROC) Stock Price, News & Analysis

Company Overview

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Key Stats

• Today's Range: $0.77 to $1.37
• 50-Day Range: $0.95 to $0.95
• 52-Week Range: $0.50 to $3.78
• Volume: 658,169 shs
• Average Volume: 46,550 shs
• Market Capitalization: $107.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PROC Stock Analysis - Frequently Asked Questions

How have PROC shares performed this year?

Procaps Group's stock was trading at $2.34 at the beginning of 2025. Since then, PROC stock has decreased by 59.4% and is now trading at $0.95.
View the best growth stocks for 2025 here.

How were Procaps Group's earnings last quarter?

Procaps Group S.A. (NASDAQ:PROC) issued its quarterly earnings data on Tuesday, December, 26th. The company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. The firm had revenue of $118.41 million for the quarter, compared to analysts' expectations of $110.40 million.

How do I buy shares of Procaps Group?

Shares of PROC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Procaps Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Procaps Group investors own include PayPal (PYPL), Intuitive Surgical (ISRG), Adobe (ADBE), Baidu (BIDU), Cogent Communications (CCOI), Datadog (DDOG) and Illumina (ILMN).

Company Calendar

• Last Earnings: 12/26/2023
• Today: 5/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PROC
• CIK: 1863362
• Web: unionacquisitiongroup.com
• Phone: 356 7995-6138
• Fax: N/A
• Employees: 4,900
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $409.92 million
• Price / Sales: 0.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 112,820,000
• Free Float: 90,372,000
• Market Cap: $107.18 million
• Optionable: Not Optionable
• Beta: -0.05